8-K: Nurix Therapeutics Reports Financial Results and Corporate Update, Highlighting Strategic Collaboration Extensions and Clinical Progress

Nurix Therapeutics announced its first quarter fiscal 2024 financial results and provided a corporate update, highlighting extended collaborations with Gilead and Sanofi, and positive clinical data for its lead drug candidate, NX-5948.

Summary

• Nurix Therapeutics reported financial results for the first quarter ending February 29, 2024, and provided a corporate update.
• The company extended its strategic collaborations with both Gilead Sciences and Sanofi, resulting in a $15 million extension fee from Gilead.
• Nurix presented new clinical data for NX-5948 at the American Association for Cancer Research (AACR) 2024 Annual Meeting, showing promising responses in patients with central nervous system lymphoma and chronic lymphocytic leukemia with CNS involvement.
• The company is part of a research team selected for the Cancer Grand Challenges competition, focusing on developing targeted protein degraders for pediatric cancers.
• Revenue for the quarter was $16.6 million, up from $12.7 million in the same period last year, primarily due to the Pfizer collaboration and increased progress with Sanofi.
• Research and development expenses increased to $50.0 million from $45.8 million, driven by clinical and manufacturing costs.
• General and administrative expenses rose to $11.8 million from $9.8 million, due to higher stock-based compensation and professional service costs.
• Net loss for the quarter was $41.5 million, or $0.76 per share, compared to $40.7 million, or $0.75 per share, in the prior year.
• As of February 29, 2024, Nurix had $254.3 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the extended collaborations, promising clinical data, and participation in the Cancer Grand Challenges competition. However, the ongoing net loss and inherent risks in drug development temper the overall sentiment.

Positives

• Strategic collaborations with Gilead and Sanofi were extended, validating Nurix
• s platform and providing additional funding.', 'New clinical data for NX-5948 showed promising responses in patients with CNS lymphoma and CLL with CNS involvement.', 'Participation in the Cancer Grand Challenges competition provides an opportunity to develop treatments for pediatric cancers.', 'The FDA lifted the partial clinical hold on the NX-2127 trial in March 2024, allowing Nurix to reinitiate enrollment.', 'Revenue increased compared to the same period last year, driven by collaborations with Pfizer and Sanofi.'

Negatives

• Net loss for the quarter increased slightly to $41.5 million from $40.7 million in the prior year.
• Research and development expenses increased due to higher clinical and manufacturing costs.
• General and administrative expenses increased due to higher stock-based compensation and professional service costs.
• Screening and enrollment of new study participants for the NX-2127 trial was paused due to a partial clinical hold by the FDA, although it has since been lifted.

Risks

• There is no guarantee that Nurix will be able to advance its drug candidates, obtain regulatory approval, and ultimately commercialize them.
• Clinical trials may not yield positive results, and the timing of results is uncertain.
• Funding for development activities may be insufficient to achieve development goals.
• Payments from collaboration partners, including milestone payments and royalties, are uncertain.
• Global business, political, and macroeconomic conditions, cybersecurity events, instability in the banking system, and global events could impact Nurix
• s business, clinical trials, financial condition, liquidity, and results of operations.', 'Nurix may not be able to protect its intellectual property.'

Future Outlook

Nurix expects to continue advancing its clinical pipeline, including presenting additional clinical data for NX-5948, defining doses for Phase 1b cohort expansion for NX-5948 and NX-1607, and reinitiating enrollment for the NX-2127 trial. The company also anticipates achieving substantial research collaboration milestones with its partners Gilead, Sanofi, and Pfizer.

Management Comments

• Nurix had a strong start to 2024 with the recent announcements of the extensions of our collaborations with both Gilead and Sanofi further validating the power of our platform and the expansion of our work in inflammatory diseases with Sanofi, including the STAT6 program, one of the most exciting targets in inflammation.
• We look forward to the continued advancement of our exciting clinical pipeline led by NX-5948 in addition to our other wholly owned and partnered programs.

Industry Context

Nurix is operating in the rapidly growing field of targeted protein modulation, with a focus on protein degradation and stabilization. This approach has gained significant attention in recent years as a potential new way to treat cancer and other diseases. The extensions of the collaborations with Gilead and Sanofi, along with the new partnership with Pfizer, demonstrate the increasing interest of large pharmaceutical companies in this area.

Comparison to Industry Standards

• Nurix
• s revenue of $16.6 million is comparable to other clinical-stage biotech companies focused on targeted protein degradation, such as Kymera Therapeutics, which reported revenue of $22.5 million in Q4 2023, and C4 Therapeutics, which reported revenue of $8.77 million in Q4 2023.', 'Nurix's net loss of $41.5 million is also in line with its peers, such as Arvinas, which reported a net loss of $68.6 million in Q4 2023.', 'Nurix's cash position of $254.3 million is relatively strong compared to some of its competitors, such as Monte Rosa Therapeutics, which had a cash position of $253.3 million as of December 31, 2023.'

Stakeholder Impact

• Shareholders may benefit from the potential long-term value creation if Nurix
• s drug candidates are successful, but they also face the risk of dilution and potential losses if the candidates fail.', 'Employees are engaged in cutting-edge research and development, which could enhance their skills and career prospects.', 'Patients with cancer and inflammatory diseases could benefit from new treatment options if Nurix's drug candidates are approved.', 'Suppliers and creditors may benefit from increased business activity as Nurix advances its programs.', 'Collaboration partners like Gilead, Sanofi, and Pfizer may benefit from access to Nurix's technology and potential new drug candidates.'

Next Steps

• Present additional clinical data for NX-5948 in mid-2024.
• Define doses for Phase 1b cohort expansion in CLL and NHL for NX-5948 in 2024.
• Complete ongoing preclinical studies for NX-5948 to enable an IND application for autoimmune indications.
• Reinitiate enrollment for the NX-2127 trial with the new chirally controlled drug substance.
• Present data from the Phase 1a dose-escalation portion of the NX-1607 trial in 2024.
• Define dose(s) to enable Phase 1b cohort expansion for NX-1607.
• Continue to achieve research collaboration milestones with Gilead, Sanofi, and Pfizer.

Key Dates

Keywords

Targeted Protein Degradation, Biopharmaceutical, Clinical Trials, Oncology, Inflammatory Diseases, BTK Degrader, E3 Ligase Inhibitor, Strategic Collaborations, Gilead Sciences, Sanofi, Pfizer, NX-5948, NX-2127, NX-1607, STAT6, Cancer Research